Kyowa Hakko signs database deal
Japan's Kyowa Hakko Kogyo has signed an agreement with US-Israeli firmCompugen to license Gencarta, the latter's annotated genome, transcriptome and proteome database and query tools. Financial terms of the multi-year agreement were not disclosed.
Seiga Itoh, senior executive officer of the drug discovery division at Kyowa Hakko, said the firm chose the Gencarta database and mining tools "because of its exceptional transcriptome analysis," adding that it will advance the firm's drug development projects. Compugen's chief executive, Mor Amitai, said the deal was significant "as it is our first Gencarta license with a large pharmaceutical company" and marks the firm's entry into the strategically-important Japanese market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze